New study tests inhaled steroid safety in tiny preemies
NCT ID NCT06589245
First seen Nov 01, 2025 · Last updated May 25, 2026 · Updated 25 times
Summary
This early-phase study tests whether an inhaled steroid called ciclesonide is safe for preterm infants (born between 23 and 30 weeks) who are on breathing machines and at risk for a chronic lung condition called bronchopulmonary dysplasia. About 30 babies will receive the drug, and researchers will closely monitor side effects such as high blood sugar, growth changes, and adrenal function. The goal is to gather safety data before larger studies can explore whether the drug helps prevent lung damage.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BRONCHOPULMONARY DYSPLASIA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Children's Mercy Kansas City
RECRUITINGKansas City, Missouri, 64108, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.